Extended Data Table 4.
Analysis of shared mutations and mutation associated noeantigens (MANA) between pre- an post-immune checkpoint blockade exposed tumors.
| Tumor Targeted by IC B (TT) | Germline Mutation | Patient Age (years) | Microsatellite Status TT | Polyps prior to ICB | Time from Last colonoscopy to ICB start | Scope on ICB | TTP from last colonoscopy (months) | TTP from last dose of ICB (months) | Post ICB Malignancy | Pathological Description | Polyp size (mm) | IHC Protein Loss | MMR Status | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | Colorectal | MLH1 | 43 | dMMR | Yes | 24 | No | 6 | 69 | Multiple cutaneous neoplasms | TA | 5 | Not possible to assess | NA |
| Patient 7 | Prostate | MSH6 | 75 | dMMR | Yes | 10 | Yes | 11 | 13 | dMMR SB Ca | TA | 10 | MSH6 | dMMR |
| Patient 11 | Esophageal | MSH2 | 69 | dMMR | No | 4 | No | 15 | 27 | dMMR Upper tract urothelial | TA | 2 | NA | NA |
| Patient 12 | Colorectal | MSH6 | 78 | dMMR | No | 1 | No | 18 | 10 | SCC MMR status UNK | TA X2 | 2, 3 | - | pMMR |
| Patient 14 | Colorectal | MLH1 | 53 | dMMR | No | 2 | Yes | 27 | 25 | dMMR Sebaceous adenoma | TVA with HGD | 25 | MLH1/ PMS2 | dMMR |
| Patient 22 | Colorectal | MSH2 | 38 | dMMR | No | <1 | Yes | 10 | 9 | - | TA | 3 | MSH2/MSH6 | dMMR |
| Patient 23 | Urothelial | MSH2 | 65 | dMMR | No | 91 | Yes | 14 | 11 | - | TA x3 | 3 x3 | Loss of MSH2 in 1 | dMMRx1, pMMRx2 |
| Patient 24 | Endometrial | MLH1 | 51 | dMMR | No | 55 | No | 6 | 11 | - | TA | 2 | PMS2 | dMMR |
| Patient 25 | Colorectal | MSH2 | 52 | dMMR | Yes | <1 | No | 22 | 20 | - | TA | 10 | MSH2/MSH6 | dMMR |
| Patient 26 | Endometrial | PMS2 | 63 | dMMR | Nil prior | Nil prior | No | NA | 7 | - | TA | 5 | - | pMMR |
| Patient 27 | Colorectal | MLH1 | 42 | dMMR | Yes | 9 | No | 31 | 3 | - | TA | 4 | - | pMMR |
| Patient 28 | Colorectal | EPCAM | 40 | dMMR | No | 4 | Yes | 39 | 22 | - | TA | 3 | - | pMMR |
| Patient 29 | Colorectal | MSH2 | 32 | dMMR | No | 1 | No | 12 | 20 | - | TA | 2 | - | pMMR |
| Patient 30 | Endometrial | MSH2 | 61 | dMMR | Nil prior | Nil prior | Yes | 5 | 4 | - | TA | 2 | - | pMMR |
| Patient 31 | Colorectal* | PMS2 | 60 | dMMR | Incomplete, obstructing primary | 2 | No | 9 | 1 | - | TVA × 1, TA ×12 | 35, 7–10×7, 7–12×5 | - | pMMR all blocks |
| Patient 32 | Urothelial | MSH6 | 62 | pMMR | Yes | 4 | Yes | 13 | 9 | - | SSP | 5 | NA | NA |
| Patient 33 | Colorectal | MSH6 | 38 | dMMR | No | 4 | Yes | 12 | 35 | - | TA | 5 | NA | NA |
| Patient 34 | Colorectal | MSH2 | 47 | dMMR | No | 1 | No | 13 | 2 | - | TA | 5 | - | pMMR |
| Patient 35 | Colorectal | MSH6 | 74 | dMMR | Yes | 0.23 | No | 16 | 0.4 | - | TA ×2 | 4, 6 | - | pMMR |
| Patient 36 | Colorectal | MLH1 | 33 | dMMR | No | 7 | Yes | 22 | 20 | - | TA | 10 | - | pMMR |
| Patient 37 | Colorectal | MSH6 | 75 | dMMR | Yes | <1 | No | 10 | 5 | - | TA x3, SA | 10,5 4,4 | NA | NA |
| Patient 38 | Gastric | MSH2, EPCAM | 77 | dMMR | Nil prior scop | Nil prior scope | Yes | 23 | 24 | - | TA x3 | 8, 2,4 | - | pMMR all blocks |
| Patient 39 | Urothelial | MSH2 | 37 | dMMR | No | 49 | No | 35 | 39 | - | TA | 5 | pMMR | |
| Patient 40 | Gastric | MSH2 | 73 | dMMR | Yes | 25 | Yes | 20 | 12 | - | TA ×3 | 5 | - | pMMR all blocks |
Tumor pairs with shared neoantigen number are aligned with the corresponding shared mutation(s) for that specific pair.